公开(公告)号：US10393754B2

公开(公告)日：2019-08-27

申请号：US13579797

申请日：2011-02-17

Applicant: Pingbo Zhang ,  Jennifer E. Van Eyk ,  Anne M. Murphy ,  Ger Stienen ,  Jolanda van der Velden ,  Viola Kooij

Inventor： Pingbo Zhang ,  Jennifer E. Van Eyk ,  Anne M. Murphy ,  Ger Stienen ,  Jolanda van der Velden ,  Viola Kooij

IPC: G01N33/68 ,  C07K16/18 ,  B82Y15/00

Abstract: This invention relates to novel phosphorylation sites in cardiac Troponin I that are associated with the onset of heart failure. The phosphorylation sites, i.e., serine 5, tyrosine 26, threonine 51, serine 166, threonine 181 and/or serine 199, can be used as biomarkers for (i) identifying subjects at risk for the development of heart failure, (ii) treating subjects having a higher than normal level of the biomarker, and (iii) monitoring therapy of a subject at risk for the development of heart failure. Also described are antibodies, reagents, and kits for carrying out a method of the present invention.

公开(公告)号：US20130101606A1

公开(公告)日：2013-04-25

申请号：US13579797

申请日：2011-02-17

Applicant: Pingbo Zhang ,  Jennifer E. Van Eyk ,  Anne M. Murphy ,  Ger Stienen ,  Jolanda van der Velden ,  Viola Kooij

Inventor： Pingbo Zhang ,  Jennifer E. Van Eyk ,  Anne M. Murphy ,  Ger Stienen ,  Jolanda van der Velden ,  Viola Kooij

IPC: G01N33/68

CPC classification number: G01N33/6887 ,  B82Y15/00 ,  C07K16/18 ,  C07K2317/34 ,  G01N2800/325 ,  Y10S977/774

Abstract: This invention relates to novel phosphorylation sites in cardiac Troponin I that are associated with the onset of heart failure. The phosphorylation sites, i.e., serine 5, tyrosine 26, threonine 51, serine 166, threonine 181 and/or serine 199, can be used as biomarkers for (i) identifying subjects at risk for the development of heart failure, (ii) treating subjects having a higher than normal level of the biomarker, and (iii) monitoring therapy of a subject at risk for the development of heart failure. Also described are antibodies, reagents, and kits for carrying out a method of the present invention.

Abstract translation: 本发明涉及与心力衰竭发作相关的心肌肌钙蛋白I中的新型磷酸化位点。 可以将磷酸化位点，即丝氨酸5，酪氨酸26，苏氨酸51，丝氨酸166，苏氨酸181和/或丝氨酸199用作生物标志物，用于（i）识别有风险发展心力衰竭的受试者，（ii）治疗 具有高于正常水平的生物标志物的受试者，以及（iii）监测患有心力衰竭发展风险的受试者的治疗。 还描述了用于实施本发明的方法的抗体，试剂和试剂盒。